PLUS THERAPEUTICS – Consensus Indicates Potential 163.1% Upside

Broker Ratings

PLUS THERAPEUTICS found using ticker (PSTV) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 6 and 5.25 with a mean TP of 5.63. Now with the previous closing price of 2.14 this is indicating there is a potential upside of 163.1%. The 50 day MA is 2.13 and the 200 moving average now moves to 2.41. The market capitalisation for the company is $10m. You can visit the company’s website by visiting:

Plus Therapeutics, a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi’s sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx’s glioblastoma treatment. The company was formerly known as Cytori Therapeutics and changed its name to Plus Therapeutics in July 2019. Plus Therapeutics was founded in 1996 and is headquartered in Austin, Texas.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index